ArticleFrontiers in pediatrics2025
Improving the quality of care of respiratory syncytial virus in the neonatal and pediatric populations globally.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- RSV prophylactics for pediatric populations: A product review and meta-analysis of real-world effectiveness.Human vaccines & immunotherapeutics · 2026Pooled it
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is the leading cause of hospitalization for bronchiolitis in infants worldwide, and age (<6 months) and underlying comorbidities (e.g., prematurity, congenital heart disease) are risk factors for severe disease. However, some centers face challenges in identifying and implementing preventative measures, and best practices, for the care of at-risk infants. Therefore, this study aimed to identify best practice examples in RSV care for neonatal and pediatric populations in leading centers globally, and to understand how these practices can be widely implemented. Following a literature review, multidisciplinary teams were interviewed in 10 centers globally (1 center per country; 40 interviews conducted between May and November 2023). Centers were included based on pre-determined criteria (e.g., type of center, services provided, focus on RSV research) to ensure a representative view of RSV care. The identified best practice interventions were critically reviewed by a group of RSV experts [healthcare professionals (HCPs) and a patient group representative] and assessed for their impact on patient care and transferability to other centers. Fifty-seven unique best practice interventions were identified, sixteen of which were prioritized, across five best practice themes: (1). Caregiver education and engagement: Provision of timely caregiver education on RSV infection and care. (2). HCP education: Provision of continuous evidence-based HCP education. (3). HCP-led RSV prophylaxis services: Additional support services to ensure at-risk infants are protected ahead of the RSV season. (4). Protocols and ways of working: Establishing evidence-based procedures to ensure best practices are followed within clinical practice. (5). Technology and innovation: Leveraging digital services to optimize care delivery and experience. This study identified interventions that may improve patient outcomes and quality of care for RSV disease in the pediatric and neonatal populations. The next steps will be to disseminate and implement best practice examples across healthcare systems and care settings globally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.